title: Etanercept-induced cystic acne.
abstract: Tumor necrosis factor α antagonists are potent biologics used to treat a variety of autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn disease, psoriasis, and psoriatic arthritis. These medications are known to have many side effects (eg, infusion reactions, cytopenia, risk for infection, heart failure); however, only a few cases of acne vulgaris have been associated with the use of these biologics, particularly infliximab and adalimumab. We report a rare case of etanercept-induced cystic acne.
authors.forename: Maria
authors.initials: M
authors.lastname: Kashat
authors.forename: Katherine
authors.initials: K
authors.lastname: Caretti
authors.affiliation: 18100 Oakwood Blvd, Ste 300, Dearborn, MI 48124, USA. jkado@med.wayne.edu.
authors.forename: Jessica
authors.initials: J
authors.lastname: Kado
mesh_terms: D000152:Acne Vulgaris / Q000139:chemically induced* / Q000188:drug therapy*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008911:Minocycline / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D008911:Minocycline; D000068800:Etanercept